ambiom s.r.o. https://validator.w3.org/feed/docs/rss2.html Clients & partners Services IMPACTWHEEL with Ambiom proceeds to Phase 2 Sample Page Home Diagnostics with a strong presence in emerging healthcare trends report by CADTH Companion diagnostics (CDx) snapshot in 2026 COVID-19’s Impact on the Diagnostics Market IVDR is here – 5 major changes to look out for Top 3 news from ASCO 2022 Companion diagnostics – status in 2022 and future outlook A year with MDR, does it stifle innovation? Life science dealmaking in 2022 NGS in clinical routine – where are we in 2022? The 4 most expensive single-dose drugs in 2022 Life science incentives; UAE vs Central Europe HTA and MEA legislation in Ukraine: New rules in access to medical technology Top 3 news from ASCO 2023 A Freedom-To-Operate analysis – do you need to bother? FDA has approved 55 new molecules in 2023 Gene therapy reimbursement status in CEE – 5/2024 FDA LDT Rule: 3 key changes for Laboratory Developed Tests (LDTs) in the US Ongoing Biotech Patent Battles in 2024 What happened with Sarepta and what does it mean for gene therapies? CDx expert: “Genomics might only be the tip of the iceberg.” My first project Cracking the Code Of Biotech Valuation – ambiom on BeyondBiotech podcast Blog ambiom presented current issues in companion diagnostics (CDx) at Central & East European Health Policy Network Oncology Workshop in Bratislava The 4 largest hospitals in CEE Pharma Valuation 101: NPV vs rNPV in Drug Development ambiom has presented the practical experience in technology transfer at the BioCentre in Zagreb, Croatia Reimbursement for biotech startups: Why is it crucial to consider it early? ambiom part of the consortium winning a €1.34m European grant. Contact Cookies & GDPR Orange Maintenance Page 7.9% of drugs entering clinical development were approved by FDA over the past decade. 6 years with DiGA – the best reimbursement framework for DTx? Case studies